Cardiovascular and Metabolism

Metabolic disorders describes a large class of diseases, including heart disease and diabetes, that involve an imbalance in proteins, lipids, carbohydrates or nucleic acids. Our current clinical program in metabolic diseases focuses on cardiovascular disease, the number one cause of morbidity and mortality in the United States and other developed countries, and muscle-growth disorders.

Robert Pordy Robert Pordy, M.D., FACP VP Clinical Sciences, Cardiovascular and Metabolism

(REGN1033/GDF8 Antibody)

REGN1033 is a fully human monoclonal antibody that specifically binds myostatin.

Myostatin is expressed in skeletal muscle. Overexpression of myostatin leads to a wasting-like phenotype, and on the other side of the spectrum, the absence of myostatin increases muscle mass in several species, including man. There are numerous conditions where muscle loss plays a pathological role in disease and/or increased muscle mass may provide a therapeutic benefit

Early studies of trevogrumab (REGN1033) in elderly people with sarcopenia demonstrated the ability to increase muscle mass, as well as muscle strength and function.


(REGN1500/ANGPTL3 Antibody)

Evinacumab is a fully human monoclonal antibody that binds to ANGPTL3.

Angiopoietin-like 3 (ANGPTL3) is expressed in the liver, and acts as a natural inhibitor of lipoprotein lipase (LPL), an enzyme involved in the breakdown of triglycerides and other lipids. Patients who have genetic conditions resulting in absent or decreased levels of ANGPTL3 have lower levels of fasting triglycerides (TGs) and low-density lipoprotein cholesterol (LDL-C).1

Evinacumab (REGN1500) is a human monoclonal antibody created with Regeneron’s VelocImmune technology platform. Evinacumab specifically binds to ANGPTL3 and prevents its inhibition of LPL, thereby increasing the breakdown of TGs.

1Minicocci, et al. Jul 2012. J Clin Endocrinol Metab. 97(7):E1266-75.

This section discusses pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been evaluated by any regulatory authorities for the indications described in this section.

Form content here please :)